Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice

Immunotherapy

Volumn 6, Issue 6, 2014, Pages 699-708

  Herbreteau, Cécile Hélène ^a   Jacquot, Frédéric ^b   Rith, Sareth ^c   Vacher, Laurent ^a   Nguyen, Ludovic ^a   Carbonnelle, Caroline ^b   Lotteau, Vincent ^d,e   Jolivet, Michel ^a   Raoul, Hervé ^b   Buchy, Philippe ^c   Saluzzo, Jean François ^a  

^a Fab'Entech   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^d CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^e UNIVERSITÉ DE LYON   (France)

Author keywords

H5N1; immunoglobulin; influenza; passive immunotherapy

Indexed keywords

IMMUNOGLOBULIN FRAGMENT; POLYCLONAL ANTIBODY; POLYCLONAL IMMUNOGLOBULIN FRAGMENT; UNCLASSIFIED DRUG; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; LD 50; MORTALITY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; BIRD; CLASSIFICATION; DOG; GENETICS; HORSE; HUMAN; IMMUNOLOGY; INFLUENZA IN BIRDS; INTRAPERITONEAL DRUG ADMINISTRATION; MDCK CELL LINE; ORTHOMYXOVIRIDAE INFECTIONS; PHYLOGENY; SPECIES DIFFERENCE; SURVIVAL; TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BIRDS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HORSES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INJECTIONS, INTRAPERITONEAL; MADIN DARBY CANINE KIDNEY CELLS; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PHYLOGENY; SPECIES SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS;

EID: 84904596446     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.40     Document Type: Article

References (44)

1. WHO. Cumulative number of confrmed human cases for avian infuenza A(H5N1) reported to WHO, 2003-2013.
2. www.who.int/infuenza/human-animal-interface/EN-GIP- 20140124CumulativeNumberH5N1cases.pdf?ua=1
3. Tran TH, Nguyen TL, Nguyen TD et al. Avian infuenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med. 350(12), 1179-1188 (2004).
4. Beigel JH, Farrar J, Han AM et al. Avian infuenza A (H5N1) infection in humans. N. Engl. J. Med. 353(13), 1374-1385 (2005).
5. Nguyen TH, Farrar J, Horby P. Person-to-person transmission of infuenza A (H5N1). Lancet 371 (9622), 1392-1394 (2008).
6. Buchy P, Mardy S, Vong S et al. Infuenza A/H5N1 virus infection in humans in Cambodia. J. Clin. Virol. 39(3), 164-168 (2007).
7. Katz JM, Lim W, Bridges CB et al. Antibody response in individuals infected with avian infuenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J. Infect. Dis. 180(6), 1763-1770 (1999).
8. Buchy P, Vong S, Chu S et al. Kinetics of neutralizing antibodies in patients naturally infected by H5N1 virus. PLoS One 5(5), e10864 (2010).
9. Gambotto A, Barratt-Boyes SM, De Jong MD, Neumann G, Kawaoka Y. Human infection with highly pathogenic H5N1 infuenza virus. Lancet 371(9622), 1464-1475 (2008).
10. Peiris JS, Cheung CY, Leung CY, Nicholls JM. Innate immune responses to infuenza A H5N1: friend or foe? Trends Immunol. 30(12), 574-584 (2009).
11. Basu A, Antanasijevic A, Wang M et al. New small molecule entry inhibitors targeting hemagglutinin-mediated infuenza A virus fusion. J. Virol. 88(3), 1447-1460 (2014).
12. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 100(2), 446-454 (2013).
13. Naughtin M, Dyason JC, Mardy S, Sorn S, Von Itzstein M, Buchy P. Neuraminidase inhibitor sensitivity and receptorbinding specifcity of Cambodian clade 1 highly pathogenic H5N1 infuenza virus. Antimicrob. Agents Chemother. 55(5), 2004-2010 (2011).
14. Mckimm-Breschkin JL, Barrett S, Pudjiatmoko et al. I222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic avian infuenza A(H5N1) viruses. PLoS One 8(6), e66105 (2013).
15. Mckimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. Reduced sensitivity of infuenza A (H5N1) to oseltamivir. Emerg. Infect. Dis. 13(9), 1354-1357 (2007).
16. De Jong MD, Bach VC, Phan TQ et al. Fatal avian infuenza A (H5N1) in a child presenting with diarrhea followed by coma. N. Engl. J. Med. 352(7), 686-691 (2005).
17. Le QM, Kiso M, Someya K et al. Avian fu: isolation of drug-resistant H5N1 virus. Nature 437(7062), 1108 (2005).
18. Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, Webby RJ. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specifc for infuenza A H5 hemagglutinin in mice. Respir. Res. 7, 126 (2006).
19. Prabhu N, Prabakaran M, Hongliang Q et al. Prophylactic and therapeutic effcacy of a chimeric monoclonal antibody specifc for H5 haemagglutinin against lethal H5N1 infuenza. Antivir. Ther. 14(7), 911-921 (2009).
20. Sakabe S, Iwatsuki-Horimoto K, Horimoto T et al. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res. 88(3), 249-255 (2010).
21. 2 in mice. Respir. Res. 7, 43 (2006).
22. Nguyen HH, Tumpey TM, Park HJ et al. Prophylactic and therapeutic effcacy of avian antibodies against infuenza virus H5N1 and H1N1 in mice. PLoS One 5(4), e10152 (2010).
23. Zhao Z, Yan F, Chen Z et al. Cross clade prophylactic and therapeutic effcacy of polyvalent equine immunoglobulin F(ab')2 against highly pathogenic avian infuenza H5N1 in mice. Int. Immunopharmacol. 11(12), 2000-2006 (2011).
24. Kong LK, Zhou BP. Successful treatment of avian infuenza with convalescent plasma. Hong Kong Med. J. 12(6), 489 (2006).
25. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for infuenza A (H5N1) infection. N. Engl. J. Med. 357(14), 1450-1451 (2007).
26. Gutierrez RA, Naughtin MJ, Horm SV, San S, Buchy P. A(H5N1) virus evolution in South East Asia. Viruses 1(3), 335-361 (2009).
27. Lang J, Attanath P, Quiambao B et al. Evaluation of the safety, immunogenicity, and pharmacokinetic profle of a new, highly purifed, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purifed, Vero-cell rabies vaccine. Acta Trop. 70(3), 317-333 (1998).
28. Quiambao BP, Dytioco HZ, Dizon RM, Crisostomo ME, Laot TM, Teuwen DE. Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purifed equine F(ab')2 fragment rabies immunoglobulin (Favirab). PLoS Negl. Trop. Dis. 2(5), e243 (2008).
29. Chippaux JP, Lang J, Amadi-Eddine S, Fagot P, Le Mener V. Short report: treatment of snake envenomations by a new polyvalent antivenom composed of highly purifed F(ab)2: results of a clinical trial in northern Cameroon. Am. J. Trop. Med. Hyg. 61(6), 1017-1018 (1999).
30. Chippaux JP, Lang J, Eddine SA et al. Clinical safety of a polyvalent F(ab')2 equine antivenom in 223 African snake envenomations: a feld trial in Cameroon. VAO (Venin Afrique de l'Ouest) Investigators. Trans. R Soc. Trop. Med. Hyg. 92(6), 657-662 (1998).
31. Chippaux JP, Massougbodji A, Stock RP, Alagon A. Clinical trial of an F(ab') polyvalent equine antivenom for African snake bites in Benin. Am. J. Trop. Med. Hyg. 77(3), 538-546 (2007).
32. Nguyen L. Production d'immunoglobulines thérapeutiques hautement purifées (ITHP): analyse d'un procédé de purifcation. Biologie Aujourd'hui 204, 55-59 (2010).
33. Grandgeorge M, Véron JL, Lutsch C et al. Preparation of improved F(ab')2 antivenoms. An example: new polyvalent European viper antivenom (equine). In: Envenomings and Their Treatments. Fondation Mérieux, France, 161-172 (1996).
34. Reed L, Muench H. A simple method of estimating ffty percent endpoints. Am. J. Hyg. 27, 493-497 (1938).
35. Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian infuenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 37(4), 937-943 (1999).
36. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, Katz JM. A mouse model for the evaluation of pathogenesis and immunity to infuenza A (H5N1) viruses isolated from humans. J. Virol. 73(7), 5903-5911 (1999).
37. Masal ova OV, Klimova RR, Chichev EV et al. Development of monoclonal antibodies to highly pathogenic avian infuenza H5N1 virus and their application to diagnostics, prophylaxis, and therapy. Acta Virol. 55(1), 3-14 (2011).
38. Thornburg NJ, Nannemann DP, Blum DL et a l. Human antibodies that neutralize respiratory droplet transmissible H5N1 infuenza viruses. J. Clin. Invest. 123(10), 4405-4409 (2013).
39. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Metaanalysis: convalescent blood products for Spanish infuenza pneumonia: a future H5N1 treatment? Ann. Intern. Med. 145(8), 599-609 (2006).
40. Chippaux JP, Goyffon M. Venoms, antivenoms and immunotherapy. Toxicon 36(6), 823-846 (1998).
41. De Haro L, Lang J, Bedry R et al. [Snake bite by European vipers. A multicenter study of tolerance to Viperfav, a new intravenous antivenom]. Ann. Fr. Anesth. Reanim. 17(7), 681-687 (1998).
42. Steel J, Lowen AC, Wang TT et al. Infuenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1(1), e00018-10 (2010).
43. Bazin-Redureau M, Pepin S, Hong G, Debray M, Scherrmann JM. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. Toxicol. Appl. Pharmacol. 150(2), 295-300 (1998).
44. Xu Y, Jia Z, Zhou L et al. Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque. Int. Immunopharmacol. 7(13), 1834-1840 (2007).